Resilient Abbott Laboratories stock holds above $116 as guidance and litigation settlement shape outlook

Abbott Laboratories Inc. (US0028241000) stock is trading in the mid-$110 range, with shares opening at $116.62 on August 21, 2026, as investors digest stronger second-quarter earnings, a raised full-year EPS outlook and a major specialty formula litigation settlement announced on August 20, 2026.

Q2 2026 earnings beat and higher EPS guidance

Per recent earnings coverage for Abbott Laboratories, the company reported adjusted earnings per share of $1.31 for the second quarter of 2026, topping consensus estimates of $1.28 and exceeding the prior-year quarter’s $1.26. Revenue in the same period reached $12.59 billion, modestly ahead of analyst expectations of $12.52 billion and highlighting steady demand across Abbott’s healthcare product portfolio.

The earnings beat was backed by solid profitability metrics, with a reported net margin of 11.65 percent and return on equity of 17.69 percent in the latest quarter. Management paired these results with a more confident outlook, raising full-year 2026 adjusted EPS guidance to a range of $5.45 to $5.60, up from the previous range and signaling mid-single-digit growth against the backdrop of 2025 results.

In its guidance framework, Abbott also maintained expectations for annual comparable revenue growth of 6.5 percent to 7.5 percent for 2026, excluding foreign currency effects. That target suggests that the second quarter’s revenue performance is broadly aligned with management’s growth ambitions, while the EPS raise underscores improving gross margin trends and operating leverage.

Analyst targets move higher on diagnostics and earnings momentum

Analyst commentary following the second-quarter release has turned more constructive, with several firms lifting their price targets on Abbott Laboratories shares alongside the stronger guidance. One detailed coverage report highlights a price target increase to $135 from $115, while other recent notes point to updated targets around $120 and $134, collectively implying upside versus the current trading level in the mid-$110s.

Current consensus data compiled from recent broker research shows Abbott Laboratories with an average rating characterized as a Moderate to Strong Buy and a consensus price target band centered in the low-$120s. One recent synthesis places the consensus target around $121.79, which represents roughly 6.8 percent potential upside from the $114.14 reference closing level cited in the same report and modest upside versus the more recent $116.62 opening print on August 21, 2026.

Market data aggregations further indicate an average target figure of $118.67 when summarizing broader coverage, a level that sits only slightly above the latest market price and suggests investors have already priced in part of the earnings and guidance improvement. The spread between the high target at $135 and the lower consensus around $118.67 reflects differing views on how far diagnostics growth, margin expansion and litigation clarity can push valuation.

Specialty formula litigation settlement reduces uncertainty

On August 20, 2026, Abbott Laboratories disclosed that it had reached agreements with three law firms to settle the Gill case and necrotizing enterocolitis claims tied to its preterm specialty formulas. The settlement covers claims involving about 2,000 infants and carries an aggregate payment commitment of $670 million, providing a clearer boundary around one of the company’s higher-profile legal exposures.

The settlement figure, while substantial in absolute terms, is manageable in the context of Abbott’s multibillion-dollar quarterly revenue base and is likely designed to limit the risk of a more prolonged courtroom process. By crystallizing a $670 million payment, Abbott reduces headline litigation risk in its pediatric nutrition portfolio and allows investors to focus more squarely on the company’s operating performance and strategic growth initiatives.

Analyst commentary summarizing the settlement notes that fundamental and cash-flow strength metrics for Abbott remained solid leading into the agreement, with the latest earnings call reinforcing momentum through a reaffirmed sales outlook, raised EPS guidance and improving gross margins. That combination of operational strength and legal-risk containment is an important part of the equity story for healthcare investors who closely track litigation overhangs in specialized formula and device segments.

Dividend, valuation metrics and capital returns

Alongside earnings and litigation developments, Abbott continues to return cash to shareholders through its dividend program. A recent quarterly dividend of $0.63 per share was paid on August 17, 2026, to shareholders of record as of July 15, 2026. On an annualized basis, the $0.63 quarterly payment translates into $2.52 per share per year, which implies a dividend yield of 2.2 percent when measured against the reference trading levels cited in recent coverage.

From a valuation standpoint, composite market data place Abbott Laboratories’ market capitalization in the high-$200 billion range, with one cross-company overview listing the figure at $229.305 billion and a price-to-earnings ratio of 26.89. That multiple reflects both the company’s diversified revenue streams in diagnostics, medical devices, nutrition and established pharmaceuticals and the premium investors are willing to pay for consistent cash generation and dividend growth potential.

The yield and valuation picture together show Abbott positioned as a blend of income and growth, with a 2.2 percent dividend yield providing a steady cash component while the raised 2026 EPS guidance and mid-single-digit revenue growth targets offer an earnings expansion angle. For many portfolio managers, that combination can be attractive compared with pure high-growth names that lack dividends or slower-growing income stocks that offer limited EPS momentum.

Current stock performance and trading context

In recent trading, Abbott Laboratories shares have shown positive momentum around the time of the second-quarter report and subsequent guidance update. One market performance summary notes that the stock rose 2.19 percent on August 21, 2026, to close or trade at about $116.64 during a broadly constructive session for equities, with the wider S&P 500 Index also posting gains. That move brought Abbott’s shares closer to the consensus target range and underscored investor approval of the latest numbers.

Multiple institutional activity reports from August 22, 2026, cite Abbott Laboratories stock opening at $116.62 on Friday, aligning with the previous day’s closing levels and indicating that the shares are holding in a tight range in the mid-$110s. These snapshots show ongoing interest from institutional investors, with one filing recounting a purchase of 1,587,904 shares valued at $144,086,000 and another detailing adjustments to existing positions.

The trading range leaves Abbott stock below the highest analyst price targets in the mid-$130s and modestly above some earlier levels around $114.14 that were referenced in prior analyst commentaries. For investors looking at entry or add points, the relationship between the latest $116.62–$116.64 pricing band and the $118.67 to $121.79 consensus target levels provides a quantified sense of upside that is neither negligible nor excessive.

Representative product: preterm specialty nutrition

Abbott Laboratories operates across several healthcare segments, and the recent litigation settlement shines a spotlight on its preterm specialty formula products. These formulas are designed to support growth and development in premature infants, targeting higher caloric density, tailored protein profiles and specific micronutrient mixes to meet the unique needs of preterm babies under clinical supervision.

In clinical practice, such specialty formulas are often used in neonatal intensive care units as part of broader nutrition protocols, complementing or substituting breast milk when medical teams deem it appropriate. The design of Abbott’s preterm formulas typically focuses on supporting weight gain trajectories, bone mineralization and overall developmental benchmarks, while balancing risks that neonatologists monitor carefully, including gastrointestinal complications.

While the company’s August 20, 2026 agreements address legal claims including necrotizing enterocolitis associated with these products, Abbott’s broader nutrition portfolio extends to infant formulas for full-term babies, pediatric supplements, adult nutrition drinks and specialized formulations for patients with chronic conditions. That breadth means the preterm segment is important but not singularly defining for the company’s financial profile, even though legal developments in this area attract significant attention.

Stock level and investor view

As of the most recent completed trading session on August 21, 2026, Abbott Laboratories stock was quoted around $116.62 on the New York Stock Exchange, with intraday commentary highlighting a 2.19 percent advance to approximately $116.64 earlier in the day. This level places the shares below the high end of current analyst price targets, which reach up to $135, and modestly below the $118.67 average target implied by consensus data, leaving scope for potential appreciation if the company delivers on its 2026 EPS range of $5.45 to $5.60 and its 6.5 percent to 7.5 percent comparable revenue growth goals.

Read more

More on Abbott Laboratories stock and its latest earnings, guidance and litigation settlement can be found in detailed market and analyst coverage published on August 21–22, 2026.

Fact box

Company: Abbott Laboratories Inc.

ISIN: US0028241000

Ticker: ABT

Exchange: New York Stock Exchange

Sector / Industry: Health care equipment and supplies

Index membership: S&P 500